Immunosuppressive therapy for severe aplastic anemia in children under the age of 3 years yields a high response rate: a North American collaborative study.

The article examines outcomes of immunosuppressive therapy (IST) in very young children diagnosed with severe aplastic anemia, focusing on those under 3 years of age.

In this age group, inherited bone marrow failure syndromes are proportionally more common and can be clinically indistinguishable from acquired (idiopathic/immune) disease at presentation. Since only acquired cases are expected to benefit from IST, misclassification has important therapeutic and prognostic implications.

Using clinical data from children treated with IST, the authors assess response rates and outcomes by age, aiming to determine whether IST is effective and appropriate in the youngest patients and whether an age cut-off could help guide treatment decisions.

The work highlights:

• The diagnostic uncertainty in early childhood SAA
• The risk of exposing IBMFS patients to ineffective IST
• The need for careful genetic and phenotypic evaluation before committing very young children to IST as first-line therapy